Total submissions: 15
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000125673 | SCV000169135 | benign | not specified | 2014-02-11 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Invitae | RCV001081073 | SCV000285356 | benign | Tuberous sclerosis 2 | 2024-01-28 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV000125673 | SCV000305199 | likely benign | not specified | criteria provided, single submitter | clinical testing | ||
Eurofins Ntd Llc |
RCV000726033 | SCV000341361 | uncertain significance | not provided | 2016-06-07 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000042525 | SCV001277607 | likely benign | Tuberous sclerosis syndrome | 2019-02-19 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases allowed determination this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. |
Ce |
RCV000726033 | SCV001501576 | likely benign | not provided | 2024-07-01 | criteria provided, single submitter | clinical testing | TSC2: BP4, BS2 |
Genome- |
RCV001081073 | SCV002039773 | benign | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV000726033 | SCV002506118 | likely benign | not provided | 2022-01-06 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV002255266 | SCV002533428 | benign | Hereditary cancer-predisposing syndrome | 2021-01-13 | criteria provided, single submitter | curation | |
All of Us Research Program, |
RCV000042525 | SCV004821013 | benign | Tuberous sclerosis syndrome | 2024-02-05 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002255266 | SCV004971741 | likely benign | Hereditary cancer-predisposing syndrome | 2021-08-09 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Tuberous sclerosis database |
RCV000042525 | SCV000066316 | not provided | Tuberous sclerosis syndrome | no assertion provided | curation | ||
Diagnostic Laboratory, |
RCV000726033 | SCV001744907 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics, |
RCV000726033 | SCV001919228 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000125673 | SCV001968709 | benign | not specified | no assertion criteria provided | clinical testing |